Prosecution Insights
Last updated: August 14, 2026

Iregene Therapeutics Ltd.

4 pending office actions • 3 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready

Portfolio Summary

4
Total Pending OAs
2
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
2
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
2
Medium (50%)
2
Easy (50%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (25%)
§102 only1 (25%)
§112 only2 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
ROGERS, ERIC JASON 2 57.3% +30.6%
SHAMEEM, GOLAM M 1 86.6% +16.0%
MONTANARI, DAVID A 1 64.8% +49.2%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18570034 OCT4 HIGH-SELECTIVITY ACTIVATOR SHAMEEM, GOLAM M

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
17999288 SERUM-FREE INDUCTION METHOD FOR SENSORY NEURON CELL ROGERS, ERIC JASON 14d
18031877 CHEMICAL CULTURE SYSTEM AND USE THEREOF ROGERS, ERIC JASON 21d
18570034 OCT4 HIGH-SELECTIVITY ACTIVATOR SHAMEEM, GOLAM M
18259238 CHEMICAL INDUCTION METHOD FOR PHOTORECEPTOR NEURON CELLS MONTANARI, DAVID A

Top Art Units

Art UnitApps
1638 2
1621 1
1632 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18570034 OCT4 HIGH-SELECTIVITY ACTIVATOR SHAMEEM, GOLAM M 1621 §102 Non-Final OA Pending Dec 13, 2023
18259238 CHEMICAL INDUCTION METHOD FOR PHOTORECEPTOR NEURON CELLS MONTANARI, DAVID A 1632 §112 Non-Final OA Pending Jun 23, 2023
18031877 CHEMICAL CULTURE SYSTEM AND USE THEREOF ROGERS, ERIC JASON 1638 §103 Final Rejection 21d Pending Apr 14, 2023
17999288 SERUM-FREE INDUCTION METHOD FOR SENSORY NEURON CELL ROGERS, ERIC JASON 1638 §112 Final Rejection 14d Pending Jan 18, 2023

Managing Iregene Therapeutics Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month